See every side of every news story
Published loading...Updated

EC grants orphan designation for Pharvaris’ deucrictibant drug

Summary by Pharmaceutical Business Review
This announcement follows the US Food and Drug Administration’s (FDA) orphan drug designation granted to deucrictibant for the same indication in March 2022. According to the company, this The post EC grants orphan designation for Pharvaris’ deucrictibant drug appeared first on Pharmaceutical Business review.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmaceutical Business review broke the news in on Wednesday, April 2, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.